High-dose chemotherapy with autologous haematopoietic stem cell transplantation in patients with isolated vitreoretinal lymphoma: a LOC network study - Summary - MDSpire

High-dose chemotherapy with autologous haematopoietic stem cell transplantation in patients with isolated vitreoretinal lymphoma: a LOC network study

  • By

  • Adam Mainguy

  • Carole Soussain

  • Valérie Touitou

  • Amin Bennedjai

  • Laurent Kodjikian

  • Hervé Ghesquières

  • Gandhi Damaj

  • Rémy Gressin

  • Jean-Baptiste Ducloyer

  • Olivier Chinot

  • Anaïs Vautier

  • Cécile Moluçon-Chabrot

  • Guido Ahle

  • Luc Taillandier

  • Jean Pierre Marolleau

  • Adrien Chauchet

  • Fabrice Jardin

  • Nathalie Cassoux

  • Denis Malaise

  • Adélaïde Toutée

  • Sara Touhami

  • Magali Le Garff-Tavernier

  • Khê Hoang-Xuan

  • Sylvain Choquet

  • Caroline Houillier

  • November 19, 2024

  • 0 min

Share

Objective:

To assess the efficacy and safety of high-dose chemotherapy with autologous haematopoietic stem cell transplantation (HCT-ASCT) in patients with isolated vitreoretinal lymphoma (VRL), a rare and challenging condition.

Key Findings:
  • Thirty-eight patients were included, with a median age of 61 years, indicating the demographic affected by VRL.
  • At HCT-ASCT, 76% of patients had a complete response (CR) to prior treatment, suggesting effective initial therapy.
  • Eighty-seven percent achieved CR after HCT-ASCT, demonstrating the potential of this treatment.
  • The study highlighted the need for a multidisciplinary approach due to the complexity of VRL treatment, emphasizing collaboration among specialists.
Interpretation:

HCT-ASCT appears to be an effective consolidation treatment for patients with isolated VRL, showing high rates of complete response and favorable survival outcomes, which may influence treatment protocols.

Limitations:
  • Retrospective design may introduce bias, potentially affecting the reliability of the findings.
  • Limited sample size may affect generalizability, suggesting caution in applying results broadly.
  • Lack of standardized treatment protocols for VRL complicates the interpretation of outcomes.
Conclusion:

HCT-ASCT is a promising therapeutic strategy for isolated VRL, warranting further prospective studies to validate these findings and explore optimal treatment protocols.

Original Source(s)

High-dose chemotherapy with autologous haematopoietic stem cell transplantation in patients with isolated vitreoretinal lymphoma: a LOC network study

  • by Adam Mainguy, Carole Soussain, Valérie Touitou, Amin Bennedjai, Laurent Kodjikian, Hervé Ghesquières, Gandhi Damaj, Rémy Gressin, Jean-Baptiste Ducloyer, Olivier Chinot, Anaïs Vautier, Cécile Moluçon-Chabrot, Guido Ahle, Luc Taillandier, Jean Pierre Marolleau, Adrien Chauchet, Fabrice Jardin, Nathalie Cassoux, Denis Malaise, Adélaïde Toutée, Sara Touhami, Magali Le Garff-Tavernier, Khê Hoang-Xuan, Sylvain Choquet, Caroline Houillier

  • November 19, 2024

Related Content

Short-term cardiotoxicity and early echocardiographic changes following autologous hematopoietic stem cell transplantation: a single-center retrospective analysis

Outcomes of critically ill pediatric patients after haploidentical stem cell transplantation

Long-term immune response to mRNA anti-SARS-CoV-2 vaccination in patients with cancer